Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11679086 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
May, 2037
(12 years from now) | |
US11103463 | CORIUM | Methods for treating alzheimer's disease with donepezil transdermal system |
Jul, 2037
(12 years from now) | |
US10300025 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | |
US10016372 | CORIUM | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Jul, 2037
(12 years from now) | |
US10307379 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | |
US9993466 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | |
US11648214 | CORIUM | Systems and methods for long term transdermal administration |
Sep, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10569034 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-61) | Jul 09, 2024 |
Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11986468 | JANSSEN BIOTECH | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | |
US11986469 | JANSSEN BIOTECH | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | |
US11207311 | JANSSEN BIOTECH | Method of treating prostate cancer |
Jul, 2037
(12 years from now) | |
US11992486 | JANSSEN BIOTECH | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10624911 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(12 years from now) | |
US11529362 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: NA
Dosage: SOLUTION; POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10398641 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(12 years from now) | |
US10849847 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(12 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10569034 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jul 09, 2024 |
Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | |
US11654106 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | |
US11925704 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: As an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 10 years and o...
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10842938 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | |
US10688244 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | |
US11771830 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: Method of treating an allergic reaction using an auto-injector
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10584112 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10584113 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
US10759778 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
US10858341 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
US10954213 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 07, 2026 |
NCE-1 date: 07 May, 2025
Market Authorisation Date: 07 May, 2021
Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11499050 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) | |
US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 08, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: 08 July, 2026
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11851437 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11970500 | BEIGENE | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
US11591340 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
US11884674 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-871) | Aug 31, 2024 |
New Indication(I-874) | Sep 14, 2024 |
New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
New Indication(I-817) | Jan 19, 2026 |
Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
New Indication(I-936) | Mar 07, 2027 |
Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) who have received at least one p...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
New Product(NP) | Apr 25, 2019 |
New Indication(I-760) | Dec 19, 2020 |
New Indication(I-792) | Jan 14, 2022 |
New Indication(I-854) | Jan 22, 2024 |
New Indication(I-873) | Sep 17, 2024 |
Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10342813 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(12 years from now) | |
US10130646 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(12 years from now) |
Drugs and Companies using CALCIUM GLUCONATE ingredient
Market Authorisation Date: 29 October, 2018
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10918694 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(12 years from now) | |
US11951153 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(12 years from now) |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11857646 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US11925695 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(12 years from now) |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11857646 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US11925695 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(12 years from now) |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 30, 2021 |
New Indication(I-800) | Jun 20, 2022 |
New Indication(I-876) | Oct 07, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11202772 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
US10413525 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
US9839626 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
US10959982 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 July, 2019
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11065198 | JANSSEN PRODS | Dispersible compositions |
Oct, 2037
(12 years from now) |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 March, 2024
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10722471 | NOVARTIS | Galenic formulations of organic compounds |
Feb, 2037
(12 years from now) |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 12 April, 2024
Treatment: Treatment of heart failure with oral pellets
Dosage: CAPSULE, PELLETS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11896562 | AZURITY | Oral amphetamine composition |
Mar, 2037
(12 years from now) | |
US11160772 | AZURITY | Oral amphetamine composition |
Mar, 2037
(12 years from now) | |
US10441554 | AZURITY | Oral amphetamine composition |
Mar, 2037
(12 years from now) |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Market Authorisation Date: 16 April, 2021
Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients
Dosage: TABLET, ORALLY DISINTEGRATING
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10947183 (Pediatric) | UCB INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(12 years from now) | |
US11759440 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
US10603290 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
US11040018 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
US11406606 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
US11786487 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 25, 2023 |
New Indication(I-887) | Mar 25, 2025 |
Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Method of reducing or ameliorating seizures in a patient by administering a liquid formulation of fenfluramine with stiripentol thereby modulating down the formation of norfenfluramine and resulting i...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10626088 | CATALYST PHARMS | Determining degradation of 3,4-diaminopyridine |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
New Patient Population(NPP) | Sep 29, 2025 |
Orphan Drug Exclusivity(ODE-223) | Nov 28, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11446246 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(12 years from now) | |
US11324696 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(12 years from now) |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 04 February, 2022
Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10632197 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(12 years from now) | |
US10293047 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(12 years from now) | |
US10842872 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(12 years from now) |
Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient
Market Authorisation Date: 09 March, 2020
Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic ane...
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) | |
US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11219662 | LA JOLLA PHARMA | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
Jan, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 21 December, 2021
Market Authorisation Date: 23 December, 2021
Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10226423 | SCILEX PHARMS | Colchicine drug-to-drug interactions |
Dec, 2037
(13 years from now) |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10987347 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10413505 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US9867815 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10894012 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10149843 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US11040032 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10016407 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10420760 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10857095 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10231961 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10933060 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10973811 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 14 December, 2017
Treatment: Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic to the mucous membranes; Method of administering a lo...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11304961 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
US10537585 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-271) | Oct 03, 2026 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11839604 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) | |
US11786508 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal administration; Acute treatment of agitation associated with schizophrenia by sublingual or buccal adminis...
Dosage: FILM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
New Indication(I-925) | Aug 18, 2026 |
Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-925) | Aug 18, 2026 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Market Authorisation Date: 30 April, 2024
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(12 years from now) | |
US10869924 (Pediatric) | PF PRISM CV | PD-L1 antagonist combination treatments |
Jul, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10894039 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US12053461 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US11364230 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US11701326 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US11918685 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US10959991 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US11471409 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US10952998 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US11484498 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
US10695329 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: Method of treating hypertension; A method of treating hypertension; Angina
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10151763 | CORCEPT THERAP | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome |
Jan, 2037
(12 years from now) | |
US10195214 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) | |
US10842800 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) | |
US12097210 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) | |
US11969435 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 17, 2015 |
Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10689377 | BRISTOL | KRas G12C inhibitors |
May, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12076323 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(12 years from now) | |
US10561659 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Treatment: Treatment of adult patients with alopecia areata
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10857159 (Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | May 24, 2021 |
New Patient Population(NPP) | Aug 18, 2024 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 24 May, 2018
Treatment: NA
Dosage: AEROSOL, FOAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10456399 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) | |
US10960004 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
New Indication(I-794) | Feb 22, 2022 |
Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Treatment: Treatment of metastatic colorectal cancer alone or with bevacizumab in severely renally impaired patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan therapy, an anti-vegf b...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10973795 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11602513 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11602512 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11400065 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Jul, 2037
(12 years from now) | |
US11986451 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US10952986 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11826335 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US12097176 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11896572 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11839597 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US12109186 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11766418 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11065224 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US10272062 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US12115143 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US12115144 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US12115142 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11504347 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US12097175 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US12115145 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11052061 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US10736866 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
US11000498 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 01, 2026 |
Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
Orphan Drug Exclusivity(ODE-494) | Oct 16, 2031 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: Treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a once-daily pharmaceutical formulation comprising an oxybate; Treatment of narcolepsy-related cataplexy or excessive da...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) | |
US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10507132 | BAUSCH AND LOMB INC | Topical administration method |
Jun, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11033551 | SUMITOMO PHARMA | Methods of treating uterine fibroids |
Sep, 2037
(12 years from now) | |
US11957684 | SUMITOMO PHARMA | Treatment of heavy menstrual bleeding associated with uterine fibroids |
Sep, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 26, 2024 |
New Indication(I-898) | Aug 05, 2025 |
New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10933060 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US9867815 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10973811 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10894012 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10420760 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10857095 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10413505 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10149843 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10016407 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10231961 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US11040032 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
New Product(NP) | Jan 10, 2023 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 10 January, 2020
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; A method for treating a subj...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(12 years from now) | |
US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(12 years from now) | |
US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(12 years from now) | |
US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia
Dosage: TABLET; POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10857212 | AMICUS THERAP US | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Aug, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10786501 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
US10449191 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
US12097198 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
US11583526 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11040004 | ALK ABELLO | Otic gel formulations for treating otitis externa |
Nov, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 10, 2018 |
New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus
Dosage: INJECTABLE, SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
Orphan Drug Exclusivity(ODE-281) | Nov 25, 2026 |
Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 14 October, 2022
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10806743 | BRAINTREE LABS | Method of administering lactitol to reduce plasma concentration of lactitol |
May, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 12, 2025 |
Drugs and Companies using LACTITOL ingredient
NCE-1 date: 13 February, 2024
Market Authorisation Date: 12 February, 2020
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: FOR SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10905662 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
US10328037 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
US10143665 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
US10548859 (Pediatric) | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Apr 30, 2016 |
New Patient Population(NPP) | Aug 14, 2018 |
Orphan Drug Exclusivity(ODE-45) | Apr 30, 2020 |
M(M-216) | Dec 22, 2020 |
Orphan Drug Exclusivity(ODE) | Aug 14, 2022 |
Orphan Drug Exclusivity(ODE-97) | Aug 14, 2022 |
ODE*(ODE*) | Dec 22, 2024 |
Orphan Drug Exclusivity(ODE-162) | Dec 22, 2024 |
Pediatric Exclusivity(PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE; GRANULE, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11851407 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
Jun, 2037
(12 years from now) | |
US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10639297 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) | |
US11974986 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) | |
US11129812 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) | |
US9867810 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 17, 2026 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of presbyopia
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10112942 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10137124 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(12 years from now) | |
US10172851 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 08, 2025 |
Orphan Drug Exclusivity(ODE-301) | May 08, 2027 |
Orphan Drug Exclusivity(ODE-302) | May 08, 2027 |
Orphan Drug Exclusivity(ODE-303) | May 08, 2027 |
New Patient Population(NPP) | May 29, 2027 |
Orphan Drug Exclusivity(ODE-409) | Sep 21, 2029 |
Orphan Drug Exclusivity(ODE-412) | Sep 21, 2029 |
Orphan Drug Exclusivity(ODE-484) | May 29, 2031 |
Orphan Drug Exclusivity(ODE-485) | May 29, 2031 |
Orphan Drug Exclusivity(ODE-487) | May 29, 2031 |
Drugs and Companies using SELPERCATINIB ingredient
NCE-1 date: 08 May, 2024
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult or pediatric patients 2 years of age or older with advanced or metastatic thyroid cancer with a ret gene fusion, as detected by an fda-approved test, who require systemic therapy an...
Dosage: CAPSULE; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11712459 | MUNDIPHARMA | Dosing regimens for treatment of fungal infections |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
New Product(NP) | Oct 20, 2026 |
New Patient Population(NPP) | Oct 20, 2026 |
Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
New Product(NP) | Jan 25, 2017 |
New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11123325 | BOTANIX SB | Formulation for soft anticholinergic analogs |
Jul, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10864194 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(12 years from now) | |
US11622959 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: TABLET; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11998639 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
US10195151 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
US10512609 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10143656 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(12 years from now) | |
US11638697 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(12 years from now) | |
US11382864 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleansing a colon and methods of using same |
Aug, 2037
(12 years from now) | |
US11033498 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 10, 2023 |
Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient
Market Authorisation Date: 10 November, 2020
Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11903994 | APELLIS PHARMS | Dosing regimens |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 22, 2026 |
New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of 15 mg pegcetacoplan monthly or every other month
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11096913 | IBSA | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(12 years from now) | |
US10537538 | IBSA | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(12 years from now) |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 15 December, 2016
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11559530 | VERITY | Oral testosterone undecanoate therapy |
Nov, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11453655 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(13 years from now) | |
US10793547 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11517564 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Dec, 2037
(13 years from now) | |
US11179367 | VERTEX PHARMS INC | Pharmaceutical compositions for treating cystic fibrosis |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jun 08, 2024 |
New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
New Product(NP) | Apr 26, 2026 |
Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cystic fibrosis in patients aged 2 to <6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering d...
Dosage: GRANULES; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11174247 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Nov, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin receptor blocker, to lower blood pressure in adult patients who are not adequately controlled on ot...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10695361 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
US11382926 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
US11007208 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-183) | Jan 21, 2025 |
New Patient Population(NPP) | Apr 25, 2025 |
New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
M(M-301) | Jul 13, 2026 |
Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: NA
Dosage: POWDER; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10813976 | HARROW EYE | Ophthalmic compositions comprising ciclosporin |
Sep, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
US9968659 (Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
M(M-115) | Apr 06, 2015 |
M(M-176) | Apr 22, 2019 |
New Indication(I-750) | Aug 25, 2020 |
New Patient Population(NPP) | Jun 17, 2022 |
Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10137127 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(12 years from now) |